A stylized globe graphic, with the EU area emphasized
ISIDORe project home / Calls / SARS-CoV-2 & COVID‑19

SARS-CoV-2 & COVID‑19

The ISIDORe consortium is pleased to announce the launch of its first call for proposals to support scientists with an interest in SARS-CoV-2 and COVID-19

About this call

Your request for free of charge transnational access to ISIDORe services for supporting and advancing your research must be focused on one of the topics listed below.

Please fill out the ISIDORe pre-application form to obtain an ISIDORe project number. You will need it to complete your application.

Applications will be evaluated, selected and implemented on a rolling basis as long as funding remains available.

SECTION 1: SURVEILLANCE & EPIDEMIC RISK MANAGEMENT

  • Topic 1.1: Understanding pandemic emergence, including research into drivers of viral evolution in human and animal populations
    This topic can be addressed with a biological or a social science approach.
  • Topic 1.2: Novel surveillance and monitoring strategies
    This topic includes but is not necessarily limited to: seroprevalence monitoring, wastewater monitoring, bioinformatic approaches to enable detecting materials (viral proteins, viral nucleic acids, etc) at low concentrations/volumes, integration of monitoring methods into coherent systems to strengthen surveillance overall.
  • Topic 1.3: Optimising responses to prevent or mitigate pandemics
    Response strategy, human resources, contact tracing and understanding the breaking of contact chains are all areas amenable to research in this area.
  • Topic 1.4: Development or validation of methods to predict antigenic drift based on genetic characterization
    This topic includes development of tools meant to predict changes in viral transmissibility of new variants and/or changes in disease severity resulting from infection with new variants and/or escape from diagnostics tools and/or escape from natural or vaccine-elicited immunity
  • Topic 1.5: *ONE HEALTH* Potential or established SARS-CoV-2 animal reservoirs
    This topic covers both domesticated and wild animals and can focus on:
    • Transmissibility among animals, transmissibility from animals to humans, and potential for spillback. Proposals addressing transmissibility/susceptibility in animals should go beyond the use of in vivo models (e.g., ACE2-based studies, explants, etc.)
    • Risk-based surveillance of all lineages of SARS-CoV-2, to identify the status of established reservoirs in domesticated and wild animals
    • The potential for recombination of SARS-CoV-2 with other coronaviruses known to infect animal species, and risk of spill over

SECTION 2: UNDERSTANDING SARS-CoV-2 & COVID-19

  • Topic 2.1: Understanding SARS-CoV-2 variants of concern and infection: characterization of newly detected variants of concern (cell tropism, competition with known variants, antigenic characterization, disease progression, immune responses, etc.)
  • Topic 2.2: Understanding the mechanisms determining the mild or severe outcome of SARS-CoV-2 and variants of concern infection
    This topic includes and has a special interest for long COVID
  • Topic 2.3: Understanding disease susceptibility in the context of co-infection
    This topic includes but is not necessarily limited to respiratory syncytial virus, influenza, etc.
  • Topic 2.4: Understanding disease susceptibility via the study of biological samples and data from SARS-CoV-2 patients

SECTION 3: DIAGNOSTICS

  • Topic 3.1: Development of low-cost, reliable diagnostic tools applicable to human population screening and based on viral infection and/or variant discrimination and/or serological response determination.
    This topic has a special interest for tools:
    • Applicable in primary care or entry points, or
    • Able to detect at least two pathogens/infections (e.g., SARS-CoV-2 & influenza) at once, or
    • That can be easily adapted to any pathogen
  • Topic 3.2: *ONE HEALTH* Development of low-cost, reliable diagnostic tools applicable to animal screening and based on viral infection and/or variant discrimination and/or serological response determination.

SECTION 4: THERAPEUTICS

  • Topic 4.1: SARS-CoV-2 prevention & therapeutic tools: Screening – Chemical optimisation – In vitro and in vivo evaluation
    This topic includes:
  • Strategies for mild/severe COVID-19 as well as long COVID
    Proposals for advancing the development of broad-spectrum antiviral therapeutic strategies are of special interest as long as they include SARS-CoV-2 and variants of concern.
    • Repurposed and novel prevention or treatment strategies
    • Antibodies or small molecules
    • Direct-acting antivirals (DAA) or host-targeted antivirals (HTA)
    • Antibodies and small molecules with a prophylactic potential are in scope
  • Topic 4.2: *CLINICAL* New intervention arm for a therapeutic trial: repurposing or innovative products for primary care, hospitalised or intensive care unit patients.

SECTION 5: VACCINES

  • Topic 5.1: Variant-proof and cross-protective SARS-CoV-2 vaccines / pan-coronavirus vaccines / pan-sarbecovirus vaccines
    This topic includes adapted or novel strategies
  • Topic 5.2: Investigating vaccination strategies towards the induction of local tissue-specific immunity and/or tissue-resident memory immune cells against SARS-CoV-2 and variants of concern
  • Topic 5.3: Investigating the impact of repeated boosters, including but not necessarily limited to the impact on “original antigenic sin” of multiple vaccinations and/or infection with specific SARS-CoV-2 variants
  • Topic 5.4: Pathophysiology of Adverse Drug Reactions after vaccination
    This topic means to address the most relevant ADRs, including but not necessarily limited to myo- or pericarditis, thrombosis with thrombocytopenia syndrome, etc.
  • Topic 5.5: Alternative immunisation routes and associated vaccine-induced immunity
  • Topic 5.6: *CLINICAL* New intervention arm for vaccine trial
    This topic is particularly intended for:
    • Optimising trial/boost trials in aged, adult and paediatric populations
    • Heterologous priming and boosting based on immune responses as well as protection
    • Exploring the need for and timing of additional doses in immunocompromised populations
    • Exploring immunogenicity after fractional doses of vaccines
    • Exploring the efficacy of vaccines in preventing long COVID and Multisystem Inflammatory Syndrome in Children (MIS-C)

SECTION 6: SOCIAL SCIENCES & EPIDEMIOLOGY

  • Topic 6.1: Understanding the behavioural and social drivers of SARS-CoV-2 vaccine and therapeutics uptake
  • Topic 6.2: Understanding community groups, structures and needs for development of inclusive, appropriate and tailored interventions

How to apply

If you wish to benefit from the support of ISIDORe, you are requested to submit proposals that will be evaluated based on their feasibility and scientific merit (independent peer review).

Three steps to get free-of-charge access to our services:

  • Browse our catalogue and identify the service that you need
  • Fill out the pre-application form visible at the bottom of each service catalogue section pages and hit the ‘SUBMIT’ button
  • After receiving an email with your ISIDORe ID number, follow the instructions to complete your application

Before you navigate our catalogue, please remember that for a pre-application submission:

  • You will need an ORCID number. If you don’t already have one, please go to orcid.org to obtain your own in a few clicks.
  • For multi-services requests, we’ll be happy to help: please contact us